证券代码：300109 证券简称：新开源 公告编号：2025-034 博爱新开源医疗科技集团股份有限公司 关于部分高级管理人员股份减持计划的预披露公告 高级管理人员邹晓文先生保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： | | 减持原 | 减持 | 股份来 | 计划减持股 | 占公司总 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | | | | 份数量不超 | 股本的比 | 减持价格 | 减持期间 | | | 因 | 方式 | 源 | | | | | | | | | | 过（股） | 例（%） | | | | | | | 非公开 | | | | 自公告日起 15 个 交易日后的 3 个 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 个人资 | 集中 | 发行、股 | | | 根据减持时 | 月内实施（2025 | | 邹晓文 | 金需求 | 竞价 ...

Group 1 - The stock of Xin Kai Yuan fell by 2.64% on August 27, with a trading volume of 457 million yuan [1] - On the same day, Xin Kai Yuan had a financing buy-in amount of 88.91 million yuan and a financing repayment of 79.23 million yuan, resulting in a net financing buy of 9.68 million yuan [1] - As of August 27, the total financing and securities lending balance of Xin Kai Yuan was 765 million yuan, with the financing balance accounting for 8.53% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Xin Kai Yuan Medical Technology Group Co., Ltd. was established on March 13, 2003, and listed on August 25, 2010, with its main business involving the research, production, and sales of PVP series products and other high-value pharmaceutical excipients [2] - The revenue composition of Xin Kai Yuan includes PVP series products (41.90%), PVPK30 (30.64%), and other diagnostic services, with a total revenue of 644 million yuan for the first half of 2025, a year-on-year decrease of 12.36% [2] - The net profit attributable to the parent company for the same period was 139 million yuan, down 34.74% year-on-year [2] Group 3 - Xin Kai Yuan has distributed a total of 900 million yuan in dividends since its A-share listing, with 607 million yuan distributed in the last three years [3]

Core Insights - The company reported a significant decline in both revenue and net profit for the first half of 2025 compared to the same period in 2024, with total revenue at 644 million yuan, down 12.36%, and net profit at 139 million yuan, down 34.74% [1][3] Financial Performance - Total revenue for Q2 2025 was 319 million yuan, a decrease of 6.16% year-on-year [1] - Net profit for Q2 2025 was 58.54 million yuan, down 36.06% year-on-year [1] - Gross margin decreased to 42.98%, down 22.06% year-on-year, while net margin fell to 21.41%, down 26.36% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 75.10 million yuan, accounting for 11.66% of revenue, a decrease of 6.18% year-on-year [1] - Earnings per share (EPS) dropped to 0.29 yuan, down 35.56% year-on-year [1] Cash Flow and Receivables - Accounts receivable represented 86.53% of the latest annual net profit, indicating a significant amount of outstanding payments [4] - The net cash flow from operating activities decreased by 52.97% due to reduced cash receipts from sales [3] - The net cash flow from investing activities increased by 165.84% due to the maturity of time deposits [3] - The net increase in cash and cash equivalents rose by 248.78%, also attributed to the maturity of time deposits [3] Return on Investment - The company's return on invested capital (ROIC) for the previous year was 8.27%, indicating average capital returns [3] - Historical data shows a median ROIC of 6.46% over the past decade, with the lowest recorded ROIC at 1.99% in 2020 [3]

Group 1 - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - The company’s controlling shareholder and actual controller did not change during the reporting period [5] - The company’s subsidiary, Beijing Liangyuan Biomedical Research Co., Ltd., received approval for clinical trials of a new drug for late-stage solid tumors [5][6] Group 2 - The company plans to distribute cash dividends of 2.493056 yuan per 10 shares, totaling approximately 121.18 million yuan, with the record date set for July 9, 2025 [5] - All directors attended the board meeting to review the report [2] - The company has ensured that the information disclosed is true, accurate, and complete [6]

Group 1 - The board of directors of Baoyao Xinkaiyuan Medical Technology Group Co., Ltd. held its 16th meeting of the 5th session on August 25, 2025, with all 9 directors present, complying with legal and regulatory requirements [1][2] - The board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's actual situation for the first half of 2025 without any false records or misleading statements [1][2] - The audit committee and the supervisory board reviewed and provided opinions on the semi-annual report, with a unanimous vote of 9 in favor and no votes against or abstentions [2]

Group 1 - The meeting of the fifth supervisory board of Boai Xinkaiyuan Medical Technology Group Co., Ltd. was held on August 25, 2025, with all three supervisors present [1][2] - The supervisory board approved the procedures for the preparation and review of the 2025 semi-annual report and its summary, confirming compliance with relevant laws and regulations [1] - The report content was deemed to accurately and completely reflect the actual situation of the listed company, with no false records or misleading statements [1]

（文章来源：证券日报） 证券日报网讯 8月26日晚间，新开源发布公告称，公司第五届董事会第十六次会议审议通过了《关于 2025年半年度报告及其摘要的议案》。 ...

Core Insights - The company reported a revenue of 644,014,332.79 yuan for the first half of 2025, representing a year-on-year decline of 12.36% [1] - The net profit attributable to shareholders of the listed company was 138,956,706.00 yuan, which reflects a year-on-year decrease of 34.74% [1]

Group 1 - The company announced that its fifth supervisory board's twelfth meeting approved the proposal regarding the 2025 semi-annual report and its summary [2]

Financial Performance - The company's operating revenue for the current reporting period is approximately 644 million yuan, a decrease from 734 million yuan in the same period last year, representing a decline of about 12.3% [1] - The net profit attributable to shareholders is approximately 139 million yuan, down from 213 million yuan year-on-year, indicating a decrease of about 34.2% [1] - The net profit after deducting non-recurring gains and losses is approximately 129 million yuan, compared to 218 million yuan in the previous year, reflecting a decline of about 40.7% [1] - The net cash flow from operating activities is approximately 74 million yuan, down 52.97% from 158 million yuan in the same period last year [24] - Basic earnings per share are 0.29 yuan, down from 0.45 yuan year-on-year [1] Asset and Liability Changes - As of the end of the current reporting period, total assets amount to approximately 4.695 billion yuan, an increase from 4.372 billion yuan at the end of the previous year [1] - The net assets attributable to shareholders are approximately 3.779 billion yuan, up from 3.638 billion yuan at the end of the previous year [1] - Long-term borrowings have increased by 674.28%, contributing to a rise in total assets ratio by 2.93 percentage points [38] - The company's inventory value is 400 million yuan, accounting for 10.59% of net assets, with an increase of approximately 22.79 million yuan [41] Profitability Metrics - The weighted average return on equity for the first half of 2025 is 3.75%, a decrease of 2.16 percentage points compared to the previous year [23] - The company's gross profit margin has shown fluctuations, with the latest data indicating a decline compared to industry averages [19] Business Segments - The company operates in two main sectors: fine chemicals and precision medicine, with a focus on producing and selling PVP series products and developing a medical service platform [9] - The revenue composition for the first half of 2025 includes various product lines, with significant contributions from PVP products and precision medical services [15] Market Valuation - As of August 26, the company's price-to-earnings ratio (TTM) is approximately 33.37, the price-to-book ratio (LF) is about 2.44, and the price-to-sales ratio (TTM) is around 6.07 [1]